Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma

Journal of Neuro-Oncology

Volumn 89, Issue 2, 2008, Pages 131-139

  Diensthuber, Marc ^a,b   Potinius, Marc ^a,b   Rodt, Thomas ^a   Stan, Alexandru C ^a   Welkoborsky, Hans J ^c   Samii, Madjid ^d   Schreyögg, Jonas ^e   Lenarz, Thomas ^a   Stöver, Timo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORDSTADT HOSPITAL   (Germany)

^d INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^e TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bcl 2; Erythropoietin; Erythropoietin receptor; Hypoxia inducible factor 1 ; Microvessel density; Olfactory neuroblastoma

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ESTHESIONEUROBLASTOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; METASTASIS; MICROSURGERY; MICROVASCULATURE; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD31; APOPTOSIS; ERYTHROPOIETIN; ESTHESIONEUROBLASTOMA, OLFACTORY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MIDDLE AGED; NASAL CAVITY; NEOVASCULARIZATION, PATHOLOGIC; NOSE NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ERYTHROPOIETIN; SURVIVAL ANALYSIS;

EID: 48749088591     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9602-9     Document Type: Article

References (37)

1. Finkelstein SD, Hirose T, VandenBerg SR (2000) Olfactory neuroblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer Press, Lyon, pp 150-152
2. Dulguerov P, Allal AS, Calcaterra TC (2001) Esthesioneuroblastoma: A meta-analysis and review. Lancet Oncol 2:683-690
3. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186
4. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A (2007) Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 50:636-641
5. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465
6. Semenza GL (2002) HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8:S62-S67
7. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565
8. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789-1806
9. Diensthuber M, Ilner T, Rodt T, Samii M, Brandis A, Lenarz T, Stöver T (2007) Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: Potential role in tumor progression. Otol Neurotol 28:559-565
10. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88:1576-1582
11. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ (1999) Signal transduction in the erythropoietin receptor system. Exp Cell Res 253:143-156
12. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
13. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T, D'Amato R (2001) Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 93:208-213
14. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nor JE (2005) Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65:5063-5069
15. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ (2007) Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther 6:101-111
16. Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A, Ponzoni M (2004) Angiogenesis in neuroblastoma. Ann N Y Acad Sci 1028:133-142
17. Diensthuber M, Brandis A, Lenarz T, Stöver T (2004) Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma. Otol Neurotol 25:359-365
18. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM (1996) Expression of erythropoietin by the human placenta. FASEB J 10:760-768
19. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T (2005) Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96:394-402
20. Chan CC, Chew EY, Shen D, Hackett J, Zhuang Z (2005) Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis 11:697-704
21. Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, Cleary ML (1993) Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 81:293-298
22. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661-1668
23. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309-314
24. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169-180
25. Kaplan EL, Meier P (1985) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
26. Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G, Hockel M (2006) Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 12:6894-6900
27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
28. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900-1908
29. Ebert BL, Bunn HF (1999) Regulation of the erythropoietin gene. Blood 94:1864-1877
30. Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW (2001) Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 61:7394-7398
31. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ (2004) Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 214:243-251
32. Youle RJ, Strasser A (2008) The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
33. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M (2000) bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 86:188-196
34. Rabbany SY, Heissig B, Hattori K, Rafii S (2003) Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 9:109-117
35. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D (2002) Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 16:1453-1455
36. Wang JH, Wu QD, Bouchier-Hayes D, Redmond HP (2002) Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. Cancer 94:2745-2755
37. Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, Harner SG, VandenBerg SR (1995) Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. Cancer 76:4-19